Intravitreal bevacizumab in refractory uveitic macular edema: one-year follow-up Cervantes-Castaneda RAA et al. - Intravitreal bevacizumab is a useful and therapeutically beneficial agent in the treatment of refractory uveitic macular edema. Some patients will require adjunctive intravitreal bevacizumab injections or the use of combination therapy with intravitreal triamcinolone acetonide. [more...]
